Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

With a market cap of $114.8 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company specializing in treatments for cystic fibrosis (CF). Its portfolio includes leading CF treatments such as Trikafta/Kaftrio, Symdeko/Symkevi, Orkambi, and Kalydeco, while its pipeline targets other conditions like sickle cell disease, type 1 diabetes, and APOL1-mediated kidney disease.

Shares of the Boston, Massachusetts-based company have underperformed the broader market over the past 52 weeks. VRTX has decreased marginally over this time frame, while the broader S&P 500 Index ($SPX) has gained 11.2%. However, VRTX stock has risen 9.4% on a YTD basis, outperforming SPX's marginal gain.